Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4613117 | 1.00 | BCHE (0.43) | BCHEACHESMN1; SMN2TDP1ALDH1A1 | |
| SCHEMBL5685792 | 0.94 | ADRB2 (0.48) | BCHEACHESMN1; SMN2TDP1ALDH1A1 | |
| SCHEMBL4614245 | 0.94 | ADRB2 (0.48) | BCHEACHESMN1; SMN2TDP1ALDH1A1 | |
| SCHEMBL4613871 | 0.94 | ADRB2 (0.48) | BCHEACHESMN1; SMN2TDP1ALDH1A1 | |
| SCHEMBL4614250 | 0.94 | ADRB2 (0.48) | BCHEACHESMN1; SMN2TDP1ALDH1A1 | |
| SCHEMBL4613866 | 0.94 | ADRB2 (0.48) | BCHEACHESMN1; SMN2TDP1ALDH1A1 | |
| SCHEMBL4613101 | 0.90 | ADRB2 (0.52) | BCHEACHEADRB2 | |
| SCHEMBL4613084 | 0.90 | ADRB2 (0.52) | BCHEACHEADRB2 | |
| SCHEMBL4615534 | 0.89 | ADRB2 (0.43) | ADRB2 | |
| SCHEMBL4615538 | 0.89 | ADRB2 (0.43) | ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1633714-B1 | 2-AMINO-PYRIDINE DERIVATIVES AS BETA-2 ADRENORECEPTOR AGONISTS | PFIZER LTD (GB) | 2008-01-23 | — | — | EP | disclosed |
| EP-1633714-B1 | 2-AMINO-PYRIDINE DERIVATIVES AS BETA-2 ADRENORECEPTOR AGONISTS | PFIZER LTD (GB) | 2008-01-23 | — | — | EP | disclosed |
| US-7067541-B2 | 2-amino-pyridine derivatives useful for the treatment of diseases | PFIZER INC (US) | 2006-06-27 | — | — | US | disclosed |
| US-20050004182-A1 | 2-Amino-pyridine derivatives useful for the treatment of diseases | PFIZER INC | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004182-A1 | 2-Amino-pyridine derivatives useful for the treatment of diseases | PAH, AADAT, IL4I1 | BCHE 1576/4885ACHE 1344/4885SMN1; SMN2 2010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.